



PRE SD06

AI Chatbot in an SCE

Shivoy Pandita, Marc Jantke

18-11-2025



Safeguarding Confidentiality

The content of this document is the sole property of entimo AG.

It may not be partially or completely duplicated, passed on to a third party, or publicized in any other way without the prior written consent of entimo AG.

This does not apply to copies which are intended for company-internal usage.

This information is provided on an “AS-IS” basis without warranty and is subject to change.

Agenda

- Problem & Motivation
- Goal
- Approach
- Use Cases
- Results
- Limitations – Lessons Learned
- Future Roadmap
- Conclusion

Problem & Motivation

Why this work matters

QC of TLFs is manual, repetitive, error-prone
SAPs + Mock Shells → complex language + structure
Pressure to shorten timelines, reduce QC cycles
AI hype vs. *regulatory reality*


Key questions

Can LLMs assist without taking over?
Can we trust AI under GxP constraints?

Goal

- Validate TLFs against SAP + mock shell
- Detect structural/method language deviations
- Provide explainable evidence, not magic answers
- Keep human QC in command

Approach



Use Cases

☰ entimiCE® FastTrack
Initial dashboard | ai_test_1 | UTC+1:00 | xmja

PDF Table 14.1-1 Summary of Demographics of Subjects in the Safety Population

PDF SAP_004.pdf

	Statistics	TRS003, 3 mg/kg IV Dose (A)	China-Approved Bevacizumab, 3 mg/kg IV Dose (B)
	N	27	29
	Mean	35.23	36.14
	SD	8.1	7.3
	Median	34.6	37.0
	Min, Max	21.0-52.0	22.0-51.0
	n (%)	0 (0.0)	0 (0.0)
	n (%)	19 (70.4%)	20 (69.0%)
	n (%)	8 (29.6%)	9 (31.0%)
	n (%)	27 (100.0%)	29 (100.0%)
	n (%)	0 (0.0%)	0 (0.0%)
	n (%)	25 (92.6%)	26 (89.7%)
	n (%)	2 (7.4%)	3 (10.3%)

Category	Statistic	TRS003, 3 mg/kg IV Infusion Dose (A)	China-Approved Bevacizumab, 3 mg/kg IV Infusion Dose (B)
Age (years)	N	xx	xx
	Mean	xx.x	xx.x
	SD	xx.x	xx.x
	Median	xx.x	xx.x
	Min, Max	xx-xx	xx-xx
Age Groups	<18	x (xx.x)	x (xx.x)
	18-40	x (xx.x)	x (xx.x)
	> 40	x (xx.x)	x (xx.x)
Ethnicity	Not Hispanic or Latino	x (xx.x)	x (xx.x)
	Hispanic or Latino	x (xx.x)	x (xx.x)
Race	White	x (xx.x)	x (xx.x)
	Black	x (xx.x)	x (xx.x)

☰
ai_test_1 (Active) ✕

Name	Parent path	Status	Version	Tags	Updated by	Updated at	Size	Type
dummy.txt	InfectiousDiseases/enticyc/CYP_1234/Cyp_Data/work/work_entjod01/log	development	1.0		realmuser	2025-10-22 09:08:11	0 B	unrestricted file
SAP_004.pdf	InfectiousDiseases/enticyc/CYP_1234/Cyp_Data/work/work_xmja/ai_test	development	1.0	sap	xmja	2025-10-22 09:13:01	1.39 MB	unrestricted file
Table 14.1-1 Summary of Demographics of Subjects in the Safety Population.pdf	InfectiousDiseases/enticyc/CYP_1234/Cyp_Data/work/work_xmja/ai_test	development	1.0	tlf	xmja	2025-10-29 22:47:59	144.32 KB	unrestricted file
Table 14.3.1-1 Frequency of Subjects Experiencing Treatment-Emergent Adverse Events.pdf	InfectiousDiseases/enticyc/CYP_1234/Cyp_Data/work/work_xmja/ai_test	development	1.0	tlf	xmja	2025-10-29 22:48:00	125.67 KB	unrestricted file
Table_10.1-1 Subject Disposition.pdf	InfectiousDiseases/enticyc/CYP_1234/Cyp_Data/work/work_xmja/ai_test	development	1.0	tlf	xmja	2025-10-29 22:48:00	124.32 KB	unrestricted file
entimiCE_FastTrack_UserGuide_3500.400.23.pdf	InfectiousDiseases/enticyc/CYP_1234/Cyp_Data/work/work_xmja/ai_test	development	1.0		xmja	2025-10-24 09:11:32	10.34 MB	unrestricted file

Subject Disposition Summary

Initial dashboard

ai_test_1 (Active)

Table_10.1-1 Su...

Table 14.3.1-1 Fr...

Table 14.1-1 Su...

ai_test_1 (Active)

Table 10.1-1 Subject Disposition

Category	TRS003, 3 mg/kg IV Infusion Dose (A)	China-Approved Bevacizumab, 3 mg/kg IV Infusion Dose (B)
Screened	30	32
Screening Failures ^{1,2}	2 (6.7%)	3 (9.4%)
Not Enrolled ^{1,3}	1 (3.3%)	0 (0.0%)
Enrolled ^{1,4}	27 (90.0%)	29 (90.6%)

Dosed

Not Dosed

Completed⁵

Number of Subjects Discontinued

Primary Reason for Discontinuation

Adverse Event

Death

Pregnancy

Protocol Deviation

Lost to Follow-up

Study Terminated by Sponsor

Non-Compliance with Study Drug

Withdrawal by Subject

Prompt Details

Relevant documents:

Path

InfectiousDiseases/enticyp/CYP_1234/Cyp_Data/work/work_xmja/ai_test/Table_10.1-1 Subject Disposition.pdf

Findings from the table:

3 subjects were screened in total, with 6 (6.5%) Screening Failures.

2. 3 subjects were not enrolled in the study, 1 in the TRS003 group and 2 in the China-Approved Bevacizumab group.

3. 84 subjects were enrolled, with 27 subjects (90.0%) in the TRS003 group, 29 (90.6%) in the China-Approved Bevacizumab group, and 28 (90.3%) in the US Licensed Avastin® group.

4. 84 subjects were dosed, with 27 subjects (90.0%) in the TRS003 group, 29 (90.6%) in the China-Approved

TLF vs SAP Comparison

entimICE FastTrack

Initial dashboard ai_test_1 (Active) Demographics_T...

Show Repository Tree

Table 14.3.1-1 Frequency of Subjects Experiencing Treatment-Emergent Adverse Events and Number of Events

MedDRA® System Organ Class MedDRA® Preferred Term	Statistic	TRS003, 3 mg/kg IV Infusion Dose (N=27)	China-Approved Bevacizumab, 3 mg/kg IV Infusion Dose (N=29)
Number of TEAEs	E	8	7
Subjects with TEAEs	n (%)	7 (25.9%)	6 (20.7%)
Infections and infestations	n (%) E	3 (11.1%) 3	2 (6.9%) 2
Nasopharyngitis	n (%) E	2 (7.4%) 2	1 (3.4%) 1
Upper respiratory tract infection	n (%) E	1 (3.7%) 1	1 (3.4%) 1
Nervous system disorders	n (%) E	3 (11.1%) 3	2 (6.9%) 2
Headache	n (%) E	2 (7.4%) 2	1 (3.4%) 1
Dizziness	n (%) E	1 (3.7%) 1	1 (3.4%) 1
Gastrointestinal disorders	n (%) E	2 (7.4%) 2	2 (6.9%) 2
Nausea	n (%) E	1 (3.7%) 1	1 (3.4%) 1
Diarrhea	n (%) E	1 (3.7%) 1	1 (3.4%) 1
General disorders and administration site conditions	n (%) E	0 (0.0%) 0	1 (3.4%) 1
Injection site pain	n (%) E	0 (0.0%) 0	1 (3.4%) 1
Fatigue	n (%) E	0 (0.0%) 0	0 (0.0%) 0

Programming Notes:
 1) SOC will be presented in descending order of overall incidence rate in terms of frequency of subjects and then in frequency of events (alphabetical order will be used in case of equ
 2) Refer to footnotes for additional instructions.

E: Number of TEAEs; N: Number of subjects dosed; n (%): Number and percent of subjects with TEAE; MedDRA®: Medical Dictionary for Regulatory Activities, version 21.0; TEA
 Each subject could only contribute once to each of the incidence rates, regardless of the number of occurrences.
 Overall: Included results from all treatment groups.
 Data source: Listing 16.2.7-1

FastTrack AI

Context: ai_test_1

Reload contexts

Validate Table 14.3.1-1 in the output against SAP_004 ordering rules. Check that all System Organ Classes (SOCs) appear in descending order of overall incidence rate, and that Preferred Terms (PTs) within each SOC also follow descending incidence order, with alphabetical order used to break ties. Report any deviations with actual vs. expected order and corresponding incidence values. Ignore formatting or totals. Conclude with one of: Fully Compliant, Partially Compliant, or Non-Compliant.

[gpt-4o:] To assess compliance with the SAP_004 ordering rules, I'll examine Table 14.3.1-1 to ensure that:

- System Organ Classes (SOCs) are listed in descending order of overall incidence rate.
- Preferred Terms (PTs) within each SOC follow descending incidence order, with alphabetical order used to break ties.

Let's review the table data provided in the context:

Overall Incidence Rates

- **Infections and infestations:** 9 (10.7%)
- **Nervous system disorders:** 8 (9.5%)
- **Gastrointestinal disorders:** 7 (8.3%)
- **General disorders and administration site conditions:** 1 (1.2%)

The SOCs appear in the correct descending order of overall incidence rate.

Preferred Terms (PTs) within SOCs

- **Infections and infestations:**
 - **Nasopharyngitis:** 5 (6.0%)
 - **Upper respiratory tract infection:** 4 (4.8%)

Correct order based on descending incidence rate.

2. **Nervous system disorders:**
- **Headache:** 5 (6.0%)
 - **Dizziness:** 3 (3.6%)

Correct order based on descending incidence rate.

3. **Gastrointestinal disorders:**
- **Nausea:** 4 (4.8%)
 - **Diarrhea:** 3 (3.6%)

Correct order based on descending incidence rate.

4. **General disorders and administration site conditions:**
- **Injection site pain:** 1 (1.2%)
 - **Fatigue:** 0 (0.0%)

Correct order based on descending incidence rate. "Fatigue" comes alphabetically after "Injection site pain," but this is not relevant since its incidence is 0.

Conclusion

The table aligns with the SAP_004 ordering rules, with SOCs and PTs correctly ordered by incidence rate. There are no deviations from the expected order.

****Compliance Status:** Fully Compliant**

Prompt Details

Relevant documents:

Path

InfectiousDiseases/entimICE/CYP_1234/Cyp_Data/work/work_xmja/ai-test/TEAE_Table_14_3_1_1.pdf

InfectiousDiseases/entimICE/CYP_1234/Cyp_Data/work/work_xmja/ai-test/SAP_004.pdf

Cancel Ok

TAAE Table

entimICE FastTrack

Initial dashboardai_test_1 (Active)

Table 10.1-1 Su...Table 14.3.1-1 Fr...Table 14.1-1 Su...ai_test_1 (Active)

Table 14.3.1-1 Frequency of Subjects Experiencing Treatment-Emergent Adverse Events and Number of Events Summarized per Treatm

MedDRA® System Organ Class MedDRA® Preferred Term	Statistic	TRS003, 3 mg/kg IV Infusion Dose (N=27)	China-Approved Bevacizumab, 3 mg/kg IV Infusion Dose (N=29)	US Licensed Avastin® (Bevacizumab) (N=26)
Number of TEAEs	E	8	7	9
Subjects with TEAEs	n (%)	7 (25.9%)	6 (20.7%)	9 (34.6%)
Infections and infestations	n (%) E	3 (11.1%) 3	2 (6.9%) 2	4 (15.4%) 4
Nasopharyngitis	n (%) E	2 (7.4%) 2	1 (3.4%) 1	2 (7.7%) 2
Upper respiratory tract infection	n (%) E	1 (3.7%) 1	1 (3.4%) 1	2 (7.7%) 2
Nervous system disorders	n (%) E	3 (11.1%) 3	2 (6.9%) 2	3 (11.5%) 3
Headache	n (%) E	2 (7.4%) 2	1 (3.4%) 1	2 (7.7%) 2
Dizziness	n (%) E	1 (3.7%) 1	1 (3.4%) 1	1 (3.8%) 1
Gastrointestinal disorders	n (%) E	2 (7.4%) 2	2 (6.9%) 2	3 (11.5%) 3
Nausea	n (%) E	1 (3.7%) 1	1 (3.4%) 1	2 (7.7%) 2
Diarrhea	n (%) E	1 (3.7%) 1	1 (3.4%) 1	1 (3.8%) 1
General disorders and administration site conditions	n (%) E	0 (0.0%) 0	1 (3.4%) 1	0 (0.0%) 0
Injection site pain	n (%) E	0 (0.0%) 0	1 (3.4%) 1	0 (0.0%) 0
Fatigue	n (%) E	0 (0.0%) 0	0 (0.0%) 0	0 (0.0%) 0

Programming Notes:

1) SOC will be presented in descending order of overall incidence rate in terms of frequency of subjects and then in frequency of events (alphabetical order will be used in case of equal rates). For each SOC, PT will be presented in ascending order of overall incidence rate in terms of frequency of subjects and then in frequency of events (alphabetical order will be used in case of equal rates).

2) Refer to footnotes for additional instructions.

E: Number of TEAEs;

Prompt Details

FastTrack AI

Context: ai_test_1

Reload contexts

Verify that the overall "Subjects with TEAEs" count for each treatment group in Table 14.3.1-1 is less than or equal to the sum of subjects across all SOC (since subjects may appear in multiple SOC). Flag only if the overall count exceeds the sum or if percentage rounding deviates by > 0.1 %.

[mistral:] Verify that the overall "Subjects with TEAEs" count for each treatment group in Table 14.3.1-1 is less than or equal to the sum of subjects across all SOC (since subjects may appear in multiple SOC). Flag only if the overall count exceeds the sum or if percentage rounding deviates by > 0.1 %.

Answer: The overall count for "Subjects with TEAEs" in each treatment group is: TRS003 (22), China-Approved Bevacizumab (20), US Licensed Avastin® (26). The sum of subjects across all SOC is 84. The overall counts are all less than or equal to the sum of subjects across all SOC. No rounding deviations exceed 0.1 %. The table is compliant.

Compare "Subjects with TEAEs" (n %) in Table 14.3.1-1 with the corresponding Safety Population N in Table 14.1-1. Calculate and report the percentage of total subjects experiencing TEAEs per treatment group to confirm internal consistency.

Model: mistral

Input:

Relevant documents:

Path
...ata/work/work_xmja/ai_test/Table 14.3.1-1 Frequency of Subjects Experiencing Treatment-Emergent Adverse Events.pdf

TLF Cross Validation

entimICE[®] FastTrack

Initial dashboard ai_test_1 (Active)

Table 10.1-1 Su... Table 14.3.1-1 Fr... Table 14.1-1 Su... ai_test_1 (Active)

Table 14.3.1-1 Frequency of Subjects Experiencing Treatment-Emergent Adverse Events and Number of Events Summarized per Treatment Group

MedDRA® System Organ Class MedDRA® Preferred Term	Statistic	TRS003, 3 mg/kg IV Infusion Dose (N=27)	China-Approved Bevacizumab, 3 mg/kg IV Infusion Dose (N=29)	US Licensed Avastin® (Bevacizumab), 3 mg/kg IV Infusion Dose (N=28)
Number of TEAEs	E			
Subjects with TEAEs	n (%)			
Infections and infestations	n (%) E			
Nasopharyngitis	n (%) E			
Upper respiratory tract infection	n (%) E			
Nervous system disorders	n (%) E			
Headache	n (%) E			
Dizziness	n (%) E			
Gastrointestinal disorders	n (%) E			
Nausea	n (%) E			
Diarrhea	n (%) E			
General disorders and administration site conditions	n (%) E	0 (0.0%) 0	1 (3.4%) 1	
Injection site pain	n (%) E	0 (0.0%) 0	1 (3.4%) 1	
Fatigue	n (%) E	0 (0.0%) 0	0 (0.0%) 0	

Programming Notes:
 1) SOC will be presented in descending order of overall incidence rate in terms of frequency of subjects and then in frequency of events (alphabetical order will be used in case of equal rates). For each SOC, PT will be presented in descending order of overall incidence rate.
 2) Refer to footnotes for additional instructions.

E: Number of TEAEs; N: Number of subjects dosed; n (%): Number and percent of subjects with TEAE; MedDRA®: Medical Dictionary for Regulatory Activities, version 21.0; TEAEs: Treatment-Emergent Adverse Events

Prompt Details

Relevant documents:

Path

- ...ata/work/work_xmja/ai_test/Table 14.3.1-1 Frequency of Subjects Experiencing Treatment-Emergent Adverse Events.pdf
- ...234/Cyp_Data/work/work_xmja/ai_test/Table 14.1-1 Summary of Demographics of Subjects in the Safety Population.pdf

Cancel Ok

FastTrack AI

Context: ai_test_1

Reload contexts

subjects experiencing TEAEs per treatment group to confirm internal consistency.

Answer:

- TRS003, 3 mg/kg IV Infusion Dose (N=27)
- TEAEs: 25 (92.6%) subjects
- Safety Population N: 27
- Percentage of total subjects experiencing TEAEs: 92.6% (n=25/27)
- China-Approved Bevacizumab, 3 mg/kg IV Infusion Dose (N=29)
- TEAEs: 22 (75.9%) subjects
- Safety Population N: 29
- Percentage of total subjects experiencing TEAEs: 75.9% (n=22/29)
- US Licensed Avastin® (Bevacizumab), 3 mg/kg IV Infusion Dose (N=28)
- TEAEs: 24 (85.7%) subjects
- Safety Population N: 28
- Percentage of total subjects experiencing TEAEs: 85.7% (n=24/28)
- Overall (N=84)
- TEAEs: 73 (87.1%) subjects
- Safety Population N: 84
- Percentage of total subjects experiencing TEAEs: 87.1% (n=73/84)

The calculated percentages of total subjects experiencing TEAEs per treatment group in Table 14.3.1-1 are consistent with the corresponding Safety Population N in Table 14.1-1 (Fully Compliant).

Model: mistral

Input:

Results

- AI successfully aligned structures + language patterns
- Detected minor terminology differences
- Identified discrepancies for human review
- Accelerated **triage stage**, not final decision

Limitations – Lessons Learned

- SAP language variability is a challenge
- Mock shell formats differ
- LLM needs domain grounding (metadata is key)
- Retrieval beats generation in regulated context

Future Roadmap

- Expand library of validation patterns/templates
- UI enhancements for reviewer workflow
- Formal performance qualification under GxP
- Wider document scope (SDRG, ADRG, define.xml)
- Prompt and Model Versioning

Conclusion

Compliance

Controlled LLM sandbox
Version-locked prompts & models
Traceable references & outputs
Human sign-off mandatory

AI in clinical QC must be:

Controlled, transparent, explainable, review-centric

Questions and Answers

Thank you for your attention!
Reach out to us in case of further questions:



Shivoy Pandita

Sales Manager | spa@entimo.de



Marc Jantke

CEO | mja@entimo.de

About entimICE FastTrack

entimICE FastTrack Clinical Data Repository and Statistical Computing Environment significantly increases the efficiency of the clinical data science processes, and supports customers to master the constantly growing study pipelines, resource bottlenecks and increasing regulatory requirements.



Experience

20+ years of industry experience in MDR/CDR/SCE
PHUSE engagement and whitepaper coverage



Flexibility

Pre-configured on best industry practices
Configurable hierarchies, workflows and permissions



Technology

Modern cloud technologies
Reliable performance, scalability and usability



Compliance

Effortless regulatory compliance
GxP audit trail, version control, history, execution trace, ...



Security

State of the art data security and data privacy
Single tenant cloud for highest data protection



Openness

Open API and standard interfaces
Custom integrations and tools